MAZE
Maze Therapeutics, Inc.40.35
+0.64+1.61%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
1.94BP/E (TTM)
-Basic EPS (TTM)
-2.56Dividend Yield
0%Recent Filings
8-K
Hoppenot named Maze Chairman
Maze Therapeutics appointed Hervé Hoppenot as a Class II director and Chairman of the Board, effective October 6, 2025, succeeding Dr. Charles Homcy, who remains a director. Hoppenot brings deep oncology expertise from leading Incyte as CEO until June 2025 and prior roles at Novartis. Compensation includes pro rata retainers of $40,000 for director and $30,000 for Chairman, plus an option for 36,000 shares vesting monthly. This leadership shift bolsters strategic oversight in biotech development.
8-K
$150M private placement announced
Maze Therapeutics announced an oversubscribed $150 million private placement on September 10, 2025, issuing 4 million shares at $16.25 each and pre-funded warrants for 5.2 million shares, closing September 12. Proceeds will fund MZE829 development in APOL1-mediated kidney disease, Phase 2 trials for MZE782 in phenylketonuria and chronic kidney disease, plus research and operations. Yet Phase 1 data for MZE782 showed robust SLC6A19 inhibition with 42-fold phenylalanine excretion boosts and eGFR dips akin to renoprotective drugs. Cash extends runway through key milestones.
8-K
Maze names new CFO Tahir
Maze Therapeutics appointed Misbah Tahir as Chief Financial Officer effective September 2, 2025, bringing his experience from IGM Biosciences and prior finance roles at Dermira and Amgen. The deal includes a $500,000 base salary, up to 40% bonus, $50,000 sign-on, and options for 325,000 shares vesting over four years. Severance covers nine months' pay outside change of control, doubling to full salary plus target bonus within it. This bolsters financial leadership amid biotech pressures.
8-K
Maze Q2 loss, strong cash
Maze Therapeutics reported Q2 2025 financials, posting a $33.7 million net loss amid ramped-up R&D spending on clinical programs, while cash reserves swelled to $264.5 million from an IPO boost. Key milestones loom: Phase 1 proof-of-mechanism data for MZE782 in PKU and CKD due Q3 2025, and initial Phase 2 results for MZE829 in APOL1-mediated kidney disease in Q1 2026. Funds stretch into H2 2027. Clinical trials advance briskly.
10-Q
Q2 FY2025 results
Maze Therapeutics posted a Q2 net loss of $33.7 million, or $0.77 per diluted share, after a $139.1 million profit in the year-ago quarter driven by $165 million in license revenue from deals with Shionogi and Trace that didn't repeat. Research and development expenses climbed 43.8% year-over-year to $28.1 million, fueled by clinical trial progress on lead candidates MZE829 (Phase 2 for APOL1-mediated kidney disease) and MZE782 (Phase 1 for CKD and PKU), while general and administrative costs rose 41.9% to $8.4 million amid public company ramp-up. Cash and equivalents swelled to $264.5 million at quarter-end, bolstered by $127.8 million net proceeds from the February 2025 IPO, with free cash flow at negative $60.3 million (derived) and a $50 million undrawn revolver extending to June 2026. The IPO closed in February 2025 for $127.8 million net cash, converting all preferred stock to common. Clinical setbacks could stall pipeline momentum.
APLM
Apollomics Inc.
17.02+0.92
ATHA
Athira Pharma, Inc.
3.88+0.03
BEAM
Beam Therapeutics Inc.
26.76-0.07
LENZ
LENZ Therapeutics, Inc.
16.70-0.38
MAIA
MAIA Biotechnology, Inc.
1.23-0.12
MLYS
Mineralys Therapeutics, Inc.
36.04+0.02
MRKR
Marker Therapeutics, Inc.
1.27-0.12
RAPP
Rapport Therapeutics, Inc.
30.76+1.16
SLNO
Soleno Therapeutics, Inc.
49.50-0.45
ZVSA
ZyVersa Therapeutics, Inc.
0.13-0.00